We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Long-term Use of Bisphosphonates Lowers Risk of Colorectal Cancer

By LabMedica International staff writers
Posted on 01 Mar 2011
Bisphosphonates, calcium-regulating drugs that inhibit bone resorption and used in the treatment of hypercalcemia and osteoporosis in humans, have been found to reduce the risk of developing colorectal cancer.

In addition to being used for treatment of osteoporosis, bisphosphonates are also used to treat bone metastases caused by breast cancer, and were recently reported to be associated with a reduced risk of the disease. More...
To see if treatment with bisphosphonates would correlate with reduced risk for other types of cancer, investigators at the Technion--Israel Institute of Technology (Haifa, Israel) evaluated the use of bisphosphonates with the risk for developing colorectal cancer.

Data on the long-term use of bisphosphonates before diagnosis by 1,866 postmenopausal female participants was extracted from the Molecular Epidemiology of Colorectal Cancer (MECC) study, a population-based case-control study in northern Israel.

Results published in the February 14, 2011, online edition of the Journal of Clinical Oncology revealed that the use of bisphosphonates for more than one year before diagnosis, but not for less than one year, was associated with a significantly reduced relative risk of colorectal cancer. This association remained statistically significant after adjustment in a model for vegetable consumption, sports activity, family history of colorectal cancer, body mass index, and use of low-dose aspirin, statins, vitamin D, and postmenopausal hormones.

Overall, the use of oral bisphosphonates for more than one year was associated with a 59% relative reduction in the risk of colorectal cancer, similar to the recently reported association of this drug class with reduction in breast cancer risk.

"We formerly identified a new class of drugs associated with a reduced risk of breast cancer,” said first author Dr. Gad Rennert, professor of medicine at the Technion--Israel Institute of Technology. "And, now, by showing a similar effect on colorectal cancer risk reduction, we can assume that this class of medications has a broad effect - not necessarily limited to a specific cancer site.”

"While the disease is generally caused by bad dietary habits and lack of physical activity, it can possibly be prevented by several medications, such as aspirin and cholesterol-lowering medication of the statins group,” said Dr. Rennert. "And now, we can add bisphosphonates to the list of tools for potential prevention of colorectal cancer.”

Related Links:

Technion-Israel Institute of Technology



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.